specialized consultants to provide a feasibility review and develop a business plan for development of a viral vector manufacturing facility in a current cell manufacturing facility

Description

{"description":" Notice Number: NOI-CC-26-002367 \n\n Description: \n\n This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. \n\n This procurement is for specialized consultants to provide a feasibility review and develop a business plan for development of a viral vector manufacturing facility in a current cell manufacturing facility. The manufacturing will encompass retroviral/lentiviral vectors, AAV and transition to future nanoparticles for Phase I and early Phase II studies conducted at the NIH Clinical Center. \n\n \n\n This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. \n\n Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. \n\n Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Susan Nsangou, Contracting Officer via email to susan.nsangou@nih.gov by close date. \n"} Solicitation Number: 26-002367 Type: Presolicitation Base Type: Presolicitation NAICS: 541990 Classification Code: R499 Response Deadline: 2026-03-10T12:00:00-04:00 Office Address: BETHESDA, MD Place of Performance: Bethesda, Maryland, 20892 POC: Susan Nsangou, susan.nsangou@nih.gov, 3014969351 {"description":" Notice Number: NOI-CC-26-002367 \n\n Description: \n\n This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. \n\n This procurement is for specialized consultants to provide a feasibility review and develop a business plan for development of a viral vector manufacturing facility in a current cell manufacturing facility. The manufacturing will encompass retroviral/lentiviral vectors, AAV and transition to future nanoparticles for Phase I and early Phase II studies conducted at the NIH Clinical Center. \n\n \n\n This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. \n\n Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government. \n\n Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Susan Nsangou, Contracting Officer via email to susan.nsangou@nih.gov by close date. \n"}